anfibatide
Peptideexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01588132)
Timeline
Indications
Mechanism of action
- Platelet glycoprotein Ib alpha chainANTAGONIST
Platelet glycoprotein Ib alpha chain antagonist
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297694 ↗
Also known as
- agkisacucetin protein, agkistrodon acutus
- anfibatide
- anfibatide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04404790 | Phase 1 | Sep 30, 2020 | Bengbu Medical College, Lee's Pharmaceutical |
| NCT04021173 | Phase 2 | Jul 31, 2019 | Lee's Pharmaceutical, Shanghai Ruijin Hospital North |
| NCT02495012 | Phase 2 | Aug 1, 2015 | Lee's Pharmaceutical |
| NCT01585259 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | Lee's Pharmaceutical |
| NCT01588132 | Phase 1 | Sep 1, 2010 | Lee's Pharmaceutical |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lee's Pharmaceutical | For profit | 5 | 5 | 2 | 2010 |
| Bengbu Medical College | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Shanghai Ruijin Hospital North | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1